PureIMS Information

PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers. PureIMS’ lead candidate, Levodopa Cyclops®, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease. One product, Colistin Cyclops®, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Other clinical programs – including Epinephrine Cyclops® for (food) allergy and impending anaphylaxis – are being explored in an early clinical stage. PureIMS also supports pharma/biotech partners, applying the Cyclops®-based inhalation route for their drug of choice.